With an APOE E3/E4 genotype, am I eligible for donanemab (Lormalzi) therapy and what ARIA monitoring and precautions are required?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

APOE E3/E4 Genotype and Donanemab Eligibility

Yes, you are eligible for donanemab (Kisunla) therapy with an APOE E3/E4 genotype, but you face an intermediate risk for amyloid-related imaging abnormalities (ARIA) that requires enhanced monitoring compared to non-carriers.

Eligibility Criteria

You meet the genetic eligibility requirements for donanemab treatment. The appropriate use recommendations specify that APOE genotyping should be performed prior to treatment primarily to inform ARIA risk stratification, not to exclude patients 1. The therapy is approved for early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia, MMSE 20-30) with biomarker-confirmed AD pathology by PET or CSF 1.

Additional Eligibility Requirements

  • Pre-treatment MRI obtained within 12 months showing:
    • ≤4 cerebral microbleeds (>4 is exclusionary)
    • No cortical superficial siderosis (presence is exclusionary)
    • No major vascular contribution to cognitive impairment 1

ARIA Risk Stratification by APOE Status

Your E3/E4 heterozygote status places you at intermediate risk for ARIA-E (edema/effusions):

  • APOE E4/E4 homozygotes: 33% ARIA-E risk 2
  • APOE E3/E4 heterozygotes (your genotype): 7.1% ARIA-E risk 2
  • Non-carriers: 4.3% ARIA-E risk 2

Recent donanemab trial data confirms that APOE ε4 allele number independently increases ARIA-E risk, with heterozygotes at approximately 4 times higher risk than non-carriers by 24 weeks 3, 4. However, this intermediate risk does not preclude treatment—it mandates more vigilant monitoring.

Required ARIA Monitoring Protocol

MRI Surveillance Schedule

Mandatory surveillance MRIs must be performed:

  • Prior to infusions 2,3,4, and 7 (approximately months 1,2,3, and 6)
  • Prior to infusion 12 for higher-risk individuals (including E3/E4 carriers)
  • At any time ARIA is clinically suspected 1

Critical Timing Consideration

58.3% of ARIA-E events occur by the third infusion (approximately month 3), making early monitoring absolutely critical 3. The majority of ARIA-E cases are detected on protocol MRI before symptoms develop—only about 17% present with symptoms prompting off-protocol imaging 2.

Clinical Monitoring for Symptomatic ARIA

Symptoms Requiring Immediate MRI

Watch for and report immediately:

  • Headache (most common symptomatic presentation)
  • Confusional state (second most common)
  • Visual disturbances
  • Gait difficulties
  • Acute decline in cognitive function 2, 3

Approximately 5.8% of donanemab-treated participants develop symptomatic ARIA-E, with 1.5% experiencing serious ARIA-E 3. Most ARIA-E is mild to moderate in radiographic severity 3.

Additional Risk Factors to Monitor

Beyond APOE status, your ARIA risk is independently influenced by:

  • Baseline microhemorrhage count (higher number = higher risk)
  • Mean arterial pressure (elevated = higher risk)
  • Antihypertensive use (protective effect)
  • Baseline amyloid plaque burden (higher = higher risk) 3

Optimize blood pressure control before and during treatment, as this is a modifiable risk factor.

Treatment Administration

  • Monthly intravenous infusions for up to 72 weeks 1, 3
  • Consider discontinuing treatment if amyloid clearance is demonstrated by amyloid PET at 12-18 months 1
  • Donanemab maintains therapeutic effect when serum concentration remains above 4.43 μg/mL 4

Management of Incident ARIA

If ARIA develops:

  • Most cases are asymptomatic and detected on surveillance MRI (approximately 50-60% of cases) 2
  • Treatment can often continue with careful monitoring and possible dose adjustment 2
  • Symptomatic cases may require temporary treatment interruption
  • Severe symptomatic cases have been treated with IV steroids with symptom resolution 2
  • Long-term cognitive outcomes in asymptomatic ARIA-E cases show no significant impact on MMSE compared to non-ARIA treated groups 2

Shared Decision-Making Considerations

The decision to initiate therapy should emphasize:

  • Modest cognitive benefit: 35-36% slowing of decline on functional scales 5
  • ARIA-E risk: 24.4% overall in donanemab trials, with your E3/E4 status conferring 7.1% risk 3, 2
  • Infusion reactions: Significantly increased risk (RR 11.90) 6
  • Treatment discontinuation rate: 3.22 times higher than placebo 6

The clinical significance of the cognitive benefits remains debated, but donanemab represents the most effective amyloid-targeting therapy currently available, with superior plaque clearance compared to other monoclonal antibodies 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.